Sign in

Trial result ·

Repeated remimazolam sedation for interstitial brachytherapy in cervical cancer: a randomized controlled trial.

Written based on 1 research study on PubMed, searched on 5 Nov 2026.

What was studied

This trial compared remimazolam and propofol for sedation. Patients had cervical cancer and got interstitial brachytherapy. Each patient had repeated sessions with sedation. Evidence on repeated remimazolam use is limited. 100 people were randomized. 91 finished all sessions and were analyzed. 46 got propofol. 45 got remimazolam. The main outcome was sedation episodes with a set adverse event.

What they found

Across 138 propofol and 135 remimazolam episodes, adverse events were less frequent with remimazolam. The risk ratio was 0.30. The confidence interval was 0.18 to 0.49. Respiratory depression was also lower. Its ratio was 0.14. Low blood pressure was lower too. Its ratio was 0.20. Remimazolam doses stayed stable across sessions. Sleep scores did not differ between groups.

What it means for patients

The authors say remimazolam went with fewer breathing and blood pressure events than propofol. They say this held across repeated sessions. They say its dose needs stayed stable.

Why it is not certain yet

The main analysis covered only those who finished all sessions. People who did not finish were left out. Sleep scores did not differ between groups. The abstract names no other limits.

Source

Repeated remimazolam sedation for interstitial brachytherapy in cervical cancer: a randomized controlled trial.

PubMed · PMID 42829852

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Insomnia publications